GlassScriptPhysician profile
William Dwight Johnson
NPI 1669586996
$7,190.27
in general payments reported to CMS, 2019-2025
25 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,324 · 2022: $1,700 · 2023: $1,684 · 2024: $1,406 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,166.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,650.47 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $684.99 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $637.23 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $549.45 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $530.61 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $458.13 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $410.14 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $381.86 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $338.87 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $244.76 | 2021-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.15 | 2021-2025 | Caplyta |
| Lundbeck LLC | $155.57 | 2021-2023 | Abilify Maintena |
| Avanir Pharmaceuticals, INC. | $153.38 | 2021-2022 | |
| Livanova USA, INC. | $129.60 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Jazz Pharmaceuticals INC. | $127.83 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $120.03 | 2021-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $105.80 | 2022-2024 | |
| Corium, LLC | $72.55 | 2024-2025 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.45 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $32.54 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $31.35 | 2024-2025 | Quviviq, Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $24.56 | 2025 | Lumryz |
| Ethicon US, LLC | $21.55 | 2022 | |
| Eisai INC. | $19.14 | 2021 | |
| Merck Sharp & Dohme LLC | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.